Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Switzerland

Roche pins Tarceva hope on Cancer Drugs Fund after NICE rejects appeal

This article was originally published in Scrip

Executive Summary

Roche says it hopes that its anticancer drug Tarceva (erlotinib) will be available in England through the Cancer Drugs Fund as a monotherapy for maintenance treatment for some non-small cell lung cancer patients. Following a failed appeal from the company, NICE, the health technology appraisal body for England and Wales, issued final and binding guidance rejecting the drug on 29 June because of doubts over the overall survival gain that the drug offers.

Table

View full table

Topics

Tags:
Cancer Switzerland
Latest Headlines

Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says

With Vertex Pain Drug Filed At FDA, Commercial Ramp Is Under Way

Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024

See All
UsernamePublicRestriction

Register

SC013498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By